Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CLAFORAN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CECLOR CD vs CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life is approximately 0.6-1.2 hours in adults with normal renal function. In neonates, it is prolonged (2-6 hours). In renal impairment, half-life extends significantly (up to 15-30 hours in anuria), requiring dose adjustment.
Renal: ~80% unchanged; biliary/fecal: ~20%
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Small amounts are eliminated in bile (<10%) and feces (<1%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic